Candel Therapeutics (CADL) Research & Development (2020 - 2023)
Historic Research & Development for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $7.3 million.
- Candel Therapeutics' Research & Development rose 4597.75% to $7.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $24.5 million, marking a year-over-year increase of 1789.1%. This contributed to the annual value of $19.3 million for FY2024, which is 2118.66% down from last year.
- As of Q4 2023, Candel Therapeutics' Research & Development stood at $7.3 million, which was up 4597.75% from $5.8 million recorded in Q3 2023.
- Candel Therapeutics' Research & Development's 5-year high stood at $7.3 million during Q4 2023, with a 5-year trough of $1.8 million in Q2 2020.
- Over the past 4 years, Candel Therapeutics' median Research & Development value was $5.0 million (recorded in 2022), while the average stood at $4.5 million.
- In the last 5 years, Candel Therapeutics' Research & Development surged by 19040.26% in 2021 and then surged by 95.99% in 2023.
- Over the past 4 years, Candel Therapeutics' Research & Development (Quarter) stood at $3.5 million in 2020, then grew by 9.05% to $3.9 million in 2021, then grew by 29.01% to $5.0 million in 2022, then skyrocketed by 45.98% to $7.3 million in 2023.
- Its Research & Development stands at $7.3 million for Q4 2023, versus $5.8 million for Q3 2023 and $5.9 million for Q2 2023.